Company intelligence / Profile preview

Innorna

Shenzhen, Guangdong, Chinainnorna.com ↗

Ownership: Private
Employees: ~200
Development stage: Phase 1

Overview

Innorna has advanced multiple mRNA/LNP-based programs into clinical development. Notably, its investigational therapy IN015 for PFIC received U.S. FDA Rare Pediatric Disease Designation in late 2024. Another candidate, IN016 for PFIC targeting a different etiological factor, previously received both RPDD and Orphan Drug Designation from the FDA. The company’s pipeline also includes candidates for infectious disease vaccines and tumor immunotherapy at various stages.[3] No published pivotal trial results as of May 2025.

Therapeutic areas: OncologyImmunologyRare DiseasesGastroenterologyInfectious Diseases
Modalities: mRNA therapeuticsLipid nanoparticle (LNP) delivery systemsRNA therapies (including gene editing and cell therapy)
Industry: Biotech

Drug pipeline

9 assets

IN006

8 more assets in the full pipeline.

Request access →

Partnerships

BeiGene – global strategic collaboration to co-develop several mRNA-LNP projects; BeiGene receives exclusive global rights to certain candidates plus non-exclusive license to use Innorna’s proprietary LNP technology.

Beyond the preview

Go deeper on Innorna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innorna.

Explore the full profile